Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Doxribtimine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 4/20 | 0.73 |
| ▸ | LMNA | P02545 | 3/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.73 |
| ▸ | TK2 | O00142 | 1/20 | 0.71 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.69 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.69 |
| ▸ | ALB | P02768 | 1/20 | 0.67 |
| ▸ | PKM | P14618 | 1/20 | 0.67 |
| ▸ | BLM | P54132 | 1/20 | 0.67 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Doxribtimine SCHEMBL3437224 | 1.00 | TK1 (0.73) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| Doxribtimine SCHEMBL778861 | 1.00 | TK1 (0.73) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| Doxribtimine SCHEMBL10382149 | 1.00 | TK1 (0.73) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| Doxribtimine SCHEMBL14596596 | 1.00 | TK1 (0.73) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| Doxribtimine SCHEMBL13497202 | 1.00 | TK1 (0.73) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| Doxribtimine SCHEMBL12718344 | 1.00 | TK1 (0.73) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| Doxribtimine SCHEMBL2722555 | 1.00 | TK1 (0.73) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| Doxribtimine SCHEMBL12296879 | 1.00 | TK1 (0.73) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| Doxribtimine SCHEMBL21078835 | 1.00 | TK1 (0.73) | TK1LMNASMN1; SMN2TK2ALOX12 | |
| Doxribtimine SCHEMBL23486 | 1.00 | TK1 (0.73) | TK1LMNASMN1; SMN2TK2ALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2337 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12139537-B2 | Antibody inducing immune tolerance, induced lymphocyte, and cell therapy agent therapeutic method using induced lymphocyte | JUNTEN BIO CO., LTD. (JP) | 2024-11-12 | — | — | US | claimed |
| EP-4426741-A1 | BCMA MONOCLONAL ANTIBODY AND THE ANTIBODY-DRUG CONJUGATE | Hangzhou DAC Biotech Co., Ltd. (CN) | 2024-09-11 | — | — | EP | claimed |
| US-20240182866-A1 | TUMOR CELL SUSPENSION CULTURES AND RELATED METHODS | Beijing Percans Oncology Co., Ltd. (CN) | 2024-06-06 | — | — | US | claimed |
| US-11982671-B2 | Identification of a T cell epitope of Prevotella copri that induces T cell responses in patients with rheumatoid arthritis | THE GENERAL HOSPITAL CORPORATION (US) | 2024-05-14 | — | — | US | claimed |
| US-11753626-B2 | Tumor cell suspension cultures and related methods | Beijing Percans Oncology Co., Ltd. (CN) | 2023-09-12 | — | — | US | claimed |
| WO-2023078021-A1 | BCMA MONOCLONAL ANTIBODY AND THE ANTIBODY-DRUG CONJUGATE | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-05-11 | — | — | WO | claimed |
| EP-4155734-A2 | METHOD | Worg Pharmaceuticals (Zhejiang) Co., Ltd. (CN) | 2023-03-29 | — | — | EP | claimed |
| US-11484581-B2 | Method to create personalized canine cancer vaccines | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2022-11-01 | — | — | US | claimed |
| US-20220260587-A1 | METHOD | APITOPE TECHNOLOGY (BRISTOL) LIMITED (GB) | 2022-08-18 | — | — | US | claimed |
| EP-3997460-A1 | METHOD | Worg Pharmaceuticals (Hangzhou) Co., Ltd. (CN) | 2022-05-18 | — | — | EP | claimed |
| EP-2373382-B1 | GNAQ TARGETED DSRNA COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION | ALNYLAM PHARMACEUTICALS INC (US) | 2017-02-15 | — | — | EP | claimed |
| EP-0928290-B9 | OLIGORIBONUCLEOTIDES AND RIBONUCLEASES FOR CLEAVING RNA | ISIS PHARMACEUTICALS INC (US) | 2005-11-09 | — | — | EP | claimed |
| EP-0928290-B1 | OLIGORIBONUCLEOTIDES AND RIBONUCLEASES FOR CLEAVING RNA | ISIS PHARMACEUTICALS INC (US) | 2005-03-30 | — | — | EP | claimed |
| EP-0891373-B1 | METHOD AND COMPOUNDS FOR INHIBITION OF RIBONUCLEASES | ENDOWMENT FOR RES IN HUMAN BIO (US) | 2003-03-12 | — | — | EP | claimed |
| EP-0420862-B1 | PHARMACEUTICAL COMPOSITION CONTAINING DEOXYRIBONUCLEOSIDES FOR WOUND HEALING | PRO NEURON INC (US) | 1993-11-24 | — | — | EP | claimed |
| US-20260144885-A1 | ANTI-LRRC15 ANTIBODIES AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2026-05-28 | — | — | US | disclosed |
| US-20260146088-A1 | ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | GENENTECH, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| WO-1988004301-A1 | alpha OLIGONUCLEOTIDES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS (FR) | 1988-06-16 | — | — | WO | disclosed |
| EP-0250486-A4 | MELPHALAN DERIVATIVES. | UNIV MELBOURNE (AU) | 1988-05-25 | — | — | EP | disclosed |
| EP-0250486-A1 | MELPHALAN DERIVATIVES | CONSOLIDATED PHARMACEUTICALS LIMITED (AU) | 1988-01-07 | — | — | EP | disclosed |